Sponsored

Radiopharm Theranostics (ASX:RAD) welcomes Dr Dimitris Voliotis as Chief Medical Officer

August 21, 2024 02:46 AM BST | By Sonal Goyal
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 Radiopharm Theranostics (ASX:RAD) welcomes Dr Dimitris Voliotis as Chief Medical Officer
Image source: Company update

Highlights

  • Dr Dimitris Voliotis has been appointed as the Chief Medical Officer of RAD.
  • Dr Voliotis has designed and executed numerous registrational trials across various oncology indications.
  • His industry experience spans global drug development from major pharma to start-ups.

 Radiopharm Theranostics Limited (ASX:RAD) has appointed Dr Dimitris Voliotis as its Chief Medical Officer (CMO). With nearly 20 years of experience in biotechnology and pharmaceuticals across Europe and the US, Dr Voliotis brings a strong focus on the radiopharmaceutical sector and 12 years of academic research in preclinical and clinical studies.

Dr Voliotis' Extensive Experience

Dr Voliotis has significant industry experience in global drug development, having worked with large, medium-sized, and start-up pharmaceutical companies. He has designed and executed multiple registrational trials across various oncology indications, including numerous investigational new drug (IND) applications and clinical trials from preclinical stages through to Phase 1-4. His work has resulted in the approval of four drugs across eight different oncology indications.

Most recently, Dr Voliotis was Senior Vice President and Head of Clinical Development at Convergent Therapeutics, a radiopharmaceutical company. Previously, he held a similar role at Zentalis Pharmaceuticals (NASDAQ:ZNTL), an oncology firm. His career also includes nearly 13 years in development roles at Germany-based pharmaceutical firm Bayer AG and Japanese firm Eisai Inc.

In addition to his corporate experience, he has provided consultancy in oncology drug development with Magnesia Partners Consulting LLC, offering expert advice on clinical development and regulatory strategy.

Dr Voliotis earned his medical degree from the University of Cologne Medical School, where he also completed a doctoral thesis in cellular biology. He is board-certified in Internal Medicine, Medical Oncology, and Hematology.

RAD shares were trading at AU$0.034 apiece at the time of writing on 21 August 2024.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

AI on the Rise: A Look at Top AI Companies and Their Stocks

Recent Articles

Investing Tips

Previous Next